ROADMAP
*R*eal world *O*utcomes across the *A*lzheimer's *D*isease *s*pectrum: a *M*ultimodal data *A*ccess *P*latform

Lausanne, 26th of February, 2016

Martin Pan MD
Biogen International GmbH

Current situation of Alzheimer's Disease (AD)

- Manufacturers invest in different interventions (nutrition, pharmaceutical, diagnostic tools, etc.)
- Disease starts 10-20 years before symptoms detected >> new trials target earlier stages of the disease
- Real world data and the care do not address the full spectrum of the disease
- Passive attitude towards care
- Not enough efforts on collection and analysis of high quality real world evidence

Available data sources to inform the real world trajectory and impact of AD are very limited

- Lack of consensus on appropriate study designs and endpoints in real world data sets
- Lack of measures transferable across studies and systems
- Lack of AD-related measures in medical records that are relevant across the spectrum of the disease
- Lack of clarity on how best to model the natural history of the disease using real world data sources



IMI-2 ROADMAP – Aims of Phase 1

- To deliver a series of data integration methods and tools for patient outcomes
- Ultimately this could provide the foundation for a Europe-wide real world evidence (RWE) platform on AD
- To develop tools for stakeholder engagement and understanding of the economic, legal and social implications
- To create an open collaboration among stakeholders that yields consensual, efficient uses of such RWE platform
- Benefit of AD patients and their caregivers


Industrial Consortium
Biogen
Lilly
NOVARTIS
Roche
janssen
Pfizer
AC IMMUNE
MERCK
Public Consortium
Observational/cohort study execution
Outcomes research
Maastricht University
UNIVERSITY OF OXFORD
Dementias Platform UK
Medical Research Council
THE UNIVERSITY OF EDINBURGH
Modelling for:
natural history of disease
health economics
LSE
IMI-2 AMYPAD
IMI-2 RADAR-AD
EPAD
European Prevention of Alzheimer's Dementia Consortium
Associated Data Providers
EMIF
Data management and integration
Informatics, statistics
Erasmus
AARHUS UNIVERSITY
UNIVERSITY OF COPENHAGEN
IXICO
UNIVERSITY OF GOTHENBURG
Project Management
SYNAPSE
Public stakeholders
HTA agencies/ payers from different archetypes
NICE National Institute for Health and Care Excellence
agencia española de medicamentos y productos sanitarios
Alzheimer Europe
IDIAP Jordi Gol
National/Regional Regulators
National/Regional Health Authorities

ROADMAP – Strong data corpus

- 6 EU Member States (Denmark, France, Netherlands, Spain, Sweden, UK)
- 75 national databases and clinical registries (∑n≈80M)
- >40 cohorts (∑≈2M)
- Studies using wearables and smart devices (∑n≈100K)
- 4 dementia relevant trials (n≈50K).



ROADMAP - Deliverables

- Define a minimum set of measureable patient outcomes
- Develop recommendations on RWE appropriate AD related cognitive, functional, and behavioral endpoints
- Identify data sources and outline a data strategy for RWE outcomes
- Develop new methods for collecting RWE data to improve health care value
- Provide recommendations for disease progression modelling